www.eisai.com website review
Improve your SEO :: free trial!
www.eisai.com is 72% geoptimaliseerd!
SEO Keyword summary for www.eisai.com/news/2020/index.html
Keywords are extracted from the main content of your website and are the primary indicator of the words this page could rank for. By frequenty count we expect your focus keyword to be eisai
Focus keyword
Short and long tail
Short Tail Keywords eisai release close |
long Tail Keywords (2 words) 2020 eisai news release us search search close contact us |
long Tail Keywords (3 words) contact us search japanese contact us release worldwide japanese news release worldwide us search close worldwide japanese contact search close close |
www.eisai.com On-Page SEO Scan
Descriptive Elements
The <head> element of a www.eisai.com/news/2020/index.html page is used to inform the browser and visitors of the page about the general meta information. The head section of the page is where we place the page title, the definition of the HTML version used, the language of in which the page is written. In the head section we can also include JavaScript and CSS (markup) files for the page.
Page title
Title length
news releaseiumlfrac eisai ltd
Meta description
Meta description legth
Meta description SEO
welcome eisai official corporate website eisais news release
Content SEO
Number of Words
Spam detected?
Headings
Heading distribution
Heading normalisation
Heading SEO impact
Emphasis (bold and italic)
Emphasis SEO impact
Images
Number of images
Images dimensions
Image alt descriptions
Images SEO impact
newsindexhtml back top hhc human health care facebook linkedin
Mobile SEO www.eisai.com/news/2020/index.html
Mobile rendering
Mobile optimizations
Responsive design detected (mobile css)
No flash detected !
Mobile improvement
Marketing / lead generation for www.eisai.com/news/2020/index.html
Social Media
Facebook shares | Facebook likes | ||
Facebook comments | Tweets | ||
Google +1 |
Conversion form
Search form
Analytics
Online presence
SERP Preview
SERP Title
SERP Link
SERP Description
Domain Level SEO
Domain name
13 characters long
Domain name SEO Impact
Path name
new found in path !
news found in path !
Structured data
Publisher Markup
Other Structured data
Website configuration
Correct processing of non-existing pages?
Favicon icon found?
HTML request without WWW redirected correctly?
Robots.txt found?
Sitemap found?
Navigation and internal links
Navigation
Url seperator
Human readable urls
Number of links
Link SEO Impact
aboutsite terms of use
|
accessibility accessibility
|
community_guidelines sns community guidelines
|
company worldwide
corporate governance
about eisai
message from top management
corporate concept
corporate information
business activities
video library
eisai at a glance
corporate executives
japan business sites
eisai the first 80 years
basic approach to corporate governance
corporate governance system
board of directors and committees
related rules
compensation for corporate executives
internal audit
products
production and logistics demand chain systems
|
hhc eisais hhc concept
|
innovation innovation
research and development rd
hhceco the hhc concept ecosystem
open innovation
corporate venture capital
eisais drug discovery research and development sites worldwide
flow of rd drug creation research
latest major rd pipeline
key therapeutic areas
clinical trials
use of digital technology
policies and guidelines
collaboration with partners
|
inquiry contact us
|
ir investors
management policy
ir library
financial data
ir events calendar
stock bond information
ir site map
mediumterm business plan eway future beyond
basic policy for capital strategy
basic policies regarding persons to control the determination of financial and business policies of the company
eisai group disclosure policy
financial reports
shareholder reports
value creation report environmental report human capital report
presentations
financial highlights
fact sheet
ir calendar
stock information
bonds and ratings
analyst coverage
general meeting of shareholders
|
news 2023 release
eisai completes construction of the 5th manufacturing building at kawashima industrial park in japanto strengthen its inhouse production function for formulating anticancer agent lenvima
lenvima lenvatinib plus keytruda pembrolizumab combination demonstrated statistically significant improvement in overall survival progressionfree survival and objective response rate versus chemotherapy in patients with advanced endometrial cancer following prior systemic therapy in phase 3 studyfirst overall survival analysis for lenvima plus keytruda combination in a phase 3 study in advanced endometrial cancer
biogen files new drug application for aducanumab in japanif approved aducanumab would become the first treatment to meaningfully change the course of alzheimers diseaseaducanumab is now under regulatory review in japan europe and the united states
eisai to present abstracts on oncology products and pipeline at 43rd annual san antonio breast cancer symposium
eisai and wren therapeutics enter into research collaboration agreement for drug discovery for synucleinopathiesthis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics ofsynuclein misfolding and aggregation
eisai to present latest data on perampanel at the 74th american epilepsy society annual meeting
abbvie and eisai announce an approval for additional indication of humira a fully human antitnf monoclonal antibody for the treatment of pyoderma gangrenosum for the first time in the world
eisai commences padico smartphone application service in japan to support the daily lives of patients with parkinsons diseasewith simple operation app records and visualizes symptoms to support communication between patients and doctors
eisai selected for membership in dow jones sustainability asia pacific index 2020 for seventh time
jyseleca filgotinib for rheumatoid arthritis launches in japana oncedaily oral jak inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies
eisai receives approval for indication expansion of antiepileptic agent fycompa for use in pediatric patients
lenvima plus keytruda demonstrated statistically significant improvement in progressionfree survival overall survival and objective response rate versus sunitinib as firstline treatment for patients with advanced renal cell carcinomalenvima plus everolimus also showed statistically significant improvement in pfs and orr endpoints versus sunitinibresults of investigational phase 3 clear trial study 307keynote581 to be presented at upcoming medical meeting
sysmex presents academic report with a view to creating a simple method of diagnosing alzheimers disease using bloodthe content presented at the 13th clinical trials on alzheimers disease ctad conference
update on fda advisory committees meeting on aducanumab in alzheimers disease
european medicines agency accepts biogens aducanumab marketing authorization application for alzheimers diseaseif approved aducanumab would become the first therapy to reduce the clinical decline of alzheimers disease and to meaningfully change the course of alzheimers disease
eisai to present latest data on pipeline assets in the area of alzheimers disease and dementia at the 13th clinical trials on alzheimers disease conference
eisai and jd health establish a joint venture company in china to implement health service platformaiming to make a new contribution through a onestop online service for people living with dementia in china
global coalition for adaptive research amgen and eisai announce first patient enrolled in international covid19 trialamgen and eisai to participate in the immune modulation domain of remapcovid an adaptive clinical trial to test interventions for patients hospitalized with covid19amgens apremilast and eisais eritoran to be evaluated across multiple international trial sites within the remap network
eisai and cogstate expand agreement for global development and commercialization of digital cognitive assessment technologies
notice regarding biogens disclosure about the submission of marketing authorization application to european medicines agency for aducanumab for alzheimers disease
supplementary new drug applications for antiepileptic drug fycompa as monotherapy for partialonset seizures pediatric indication for partialonset seizures accepted in china
the university of tokyo and eisai announce research collaboration for the development and drug discovery of targeted protein degradation technologyestablishment of social cooperation program protein degradation drug discovery
industryacademiagovernment joint development agreement aiming for drug discovery for covid19 utilizing eritoran and e6011 concluded nonclinical research activities commenceadopted for the public call for amed development of therapeutic drugs for the novel coronavirus infection covid19
eisai and seikagaku enter into agreement for the marketing alliance of si613 a treatment of osteoarthritis in south korea
jyseleca filgotinib approved in japan for rheumatoid arthritisfilgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials
eisai receives positive opinion from emas chmp on use of antiepileptic agent fycompa in pediatric patients
eisai and merck present firsttime data from two studies evaluating keytruda pembrolizumab plus lenvima lenvatinib in seven different tumor types at esmo virtual congress 2020new results include findings from the phase 2 leap004 trial showing an orr of 214 in patients with unresectable or advanced melanoma who had previously progressed on an antipd1pdl1 therapy
eisai presents latest data of phase i clinical trial on liposomal formulation of anticancer agent halaven eribulin at esmo virtual congress 2020
eisai establishes pharma sales subsidiary in vietnam
eisai to present abstracts on oncology products and pipeline at esmo virtual congress 2020
eisai to take over manufacturing and marketing approval for equfina 50mg tablets safinamide mesilate in japan from meiji seika pharma
relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productseisai to launch sahne medical spray and sahne medical creamsahne medical spray is the first otc drug spraytype lotion containing heparinoid
eisai to present latest data of lemborexant at 34th annual sleep meeting sleep2020
fda accepts biogens aducanumab biologics license application for alzheimers disease with priority reviewpriority review accelerates fda review time with a prescription drug user fee act pdufa target action on march 7 2021if approved aducanumab would be the first treatment to meaningfully change the course of alzheimers disease
eisai supports relief efforts for the heavy rain event of july 2020 in japan
application for additional indication of anti cancer agent lenvima for unresectable thymic carcinoma submitted in japan
eisai and dena to provide smartphone app easiit app through business alliance agreementeisai dementia platform easiit commences
eisai listed for 19th consecutive year in ftse4good index series an index for socially responsible investment
eisai to present latest data on pipeline assets in the area of alzheimers disease and dementia at the alzheimers association international conference aaic 2020
smartphone app for vital signs measurement of patients with the novel coronavirus infection experimental study project adopted as amed projectpreventing medical infrastructure collapse by a monitoring system linked to line
initiation of new phase iii clinical study ahead 345 of ban2401 preclinical asymptomatic alzheimers disease
industryacademiagovernment joint development agreement aiming for drug discovery for systemic lupus erythematosus by practical application of tolllike receptor research concludedresearch activities commence
biogen completes submission of biologics license application to fda for aducanumab as a treatment for alzheimers diseaseif approved aducanumab would be the first treatment with the potential to meaningfully change the course of alzheimers disease
eisai and merck receive complete response letter for lenvima lenvatinib plus keytruda pembrolizumab combination as firstline treatment for unresectable hepatocellular carcinoma
eisai submits marketing authorization application in japan for anticancer agent tazemetostat for ezh2 gene mutationpositive follicular lymphoma
new drug application for inhouse developed new antiinsomnia drug dayvigo accepted in hong kongfirst new drug application for dayvigo in asia outside japan
eisai to launch inhouse developed new antiinsomnia drug dayvigo lemborexant with indication for insomnia in japan
new fine granule formulation of antiepileptic drug fycompa launched in japan
remapcap to partner with eisai on innovative trial to combat covidgcar eisai and upmc on behalf of remapcap investigator network announce eritorans inclusion in remapcovid an adaptive clinical trial to test interventions for patients with moderate and severe covid infectioneisais eritoran selected as the first investigational immune modulation therapy to be evaluated across multiple international trial sites
position and policy regarding reduction in the trading unit of the companys shares
eisai receives approval for parkinsons disease treatment equfina in south korea
shelf registration for issuance of stock options
continuation of policy for protection of the companys corporate value and common interests of shareholders shareholder rights plan
eisai to support countermeasures against the spread of the novel coronavirus infection in africasupport for continuation of elimination activities for neglected tropical diseases and support for development and popularization of mobile health platform
brain performance brainhealth selfcheck tool nouknow to be used in beauty salons
eisai launches new insomnia drug dayvigo lemborexant civ in the united states as a treatment option for adults with insomnia
abbvie and eisai announce an approval for partial changes in the marketing approval of humira a fully human antitnf monoclonal antibody concerning the dosage and administration related to the indication of hidradenitis suppurativa
results from lenvima lenvatinib plus keytruda pembrolizumab trials in unresectable hepatocellular carcinoma and advanced renal cell carcinoma to be presented at 2020 asco annual meeting
the effect of seii evokes the joy of eatingeisai to launch new selbelle premium tablets and new selbelle premium fine granulesthe first otc product containing the same amount of stomachprotecting teprenone as for medical purposes
eisai to present data on oncology pipeline and products at asco annual meeting
eisai selected as most honored company and the first place of the sector in the alljapan executive team best ir company ranking by institutional investor magazine
eisai and seikagaku enter into agreement for the codevelopment and marketing alliance of si613 a treatment of osteoarthritis in china
eisai submits marketing authorization application in japan for anticancer agent denileukin diftitox genetic recombinant for cutaneous tcell lymphoma and peripheral tcell lymphoma
discovery research on multikinase inhibitor lenvatinib honored with psj award for drug research and development 20
eisai to launch digital tool nouknow in japan for regular selfassessment of brain performance brain health
allcase surveillance condition for approval of actonel 175 mg tablets for treatment of pagets disease of bone cleared in japan
eisai and fuji yakuhin conclude license agreement concerning the development and distribution of dotinurad a treatment for hyperuricemia and gout in china
eisai receives the presidents award of the japan technoeconomics society at the 8th technology management and innovation awardsfor its contributions towards patients with liver disease through the eisaioriginated orally available kinase inhibitor lenvima
eisai to support counter measures for chinas novel coronavirusassociated pneumonia spread in china
eisai commences joint research and development of cancer gene panel test with personal genome diagnostics inc using liquid biopsy to accelerate nextgeneration drug discovery and development
dayvigo lemborexant approved for treatment of insomnia in japannonsedative orexin receptor antagonist demonstrates effectiveness for both sleep onset and sleep maintenance
approval of antiepileptic drug fycompa in japan for monotherapy and pediatric indications for partialonset seizures as well as a new formulation
eisai rated a the highest rating in the cdp climate change report 2019
launch of anticancer agent halaven in china
fycompa for adjunctive treatment of partial onset seizures launched in china
2022 release
2021 release
2020 release
2019 release
2018 release
2017 release
2016 release
2015 release
2014 release
2013 release
2012 release
2011 release
2010 release
2009 release
2008 release
2007 release
|
privacy privacy policy
read more
|
sitemap sitemap
|
sustainability sustainability
message from top management
eisais sustainability
sustainability management
initiatives for improving access to medicines
environment
society
governance
esg data report
thirdparty assessment
system for promoting sustainability
eisais materiality material topics
sustainability advisory board
initiatives for sustainable development goals
member organizations and initiatives that engage in sustainabilityrelated activities
our concept for access to medicines
initiatives for elimination of neglected tropical diseases
initiatives for improving access to medicines for noncommunicable diseases
research development for improving access to medicines
environmental management
climate countermeasure
establishment of a recyclingoriented society
management of chemical substances
biodiversity conservation
respect for human rights
relationship with customers
relationship with our employees
relationship with business partners
relationship with industry associations and patient groups advocacy
relationship with people throughout society
compliance and risk management
global tax policy
information security
targets and results
esg data and independent assurance
gri content index
|
www.eisai.com |
Links to external pages
Outloing links
reg18.smp.ne.jp
www.eisai.co.jp
www.twitter.com
SEO Advice for www.eisai.com
In this section we provide pointers on how you can to optimize your web page so it can be found more easily by search engines and how to make it rank higher by optimizing the content of the page itself. For each of the individual criteria the maximum score is 100%. A score below 70% is considered to be indication that the page is not complying with general SEO standards and should be evaluated and/or fixed. Not every factor is weighted the same and some are not as important as others. Relatively unimportant factors like meta keywords are not included in the overall score.
Item | Factor | Pointers | |
---|---|---|---|
PageTitle | 100% | Far too many sites lack a page title. A page title is the first thing that shows in the search results so always use the title element. | |
Title relevance | 65% | A title should reflect the contents of a site. This site has a 50 % match | |
Title Length | 100% | Limit your title to anywhere between 40 and 70 characters. Your title was 51 characters long | |
Meta Description | 100% | A meta description is the second element that shows in the search results so always use the meta description. | |
Meta description length | 60% | The meta description should be between 145 and 160 characters. This meta description is 85 characters long. | |
Meta description relevance | 90% | Meta Description should reflect the contents of a site. This site has a 50 % match | |
Number of internal links | 30% | Linking to internal pages makes pages easier to find for search engines. Try to keep the number of links on your page roughly below 100. There are 282 internal links on this page. | |
Folder structure | 100% | We found a folder structure in the links on your page. A good folder structure makes a site easier to navigate. We found 12 level 1 folders and 105 folders above or in the first level of navigation. | |
Headings | 100% | Headers should reflect the contents of a site. This site has a 75 % match | |
Links | 8% | Link anchors should to some degree reflect the contents of a site. This site has a 4 % match | |
Image alt tags | 31% | Image alt tags should to some degree reflect the contents of a site. This site has a 11 % match | |
Bold and italic | 100% | Bold and italic tags should reflect the contents of a site to some degree. This site has a 100 % match | |
Html ratio | 100% | Try to keep the html / text ratio as low as possible. More html means longer loading times. Layout should be handled in a serpate css file | |
Image descriptions | 22% | 22.222222222222 % of all images have been described via the "alt" attribute. Describing images with relevant text may lead to better results in the search engines. | |
Page errors | 100% | Pages with no errors display significantly faster on most browsers. We detected 0 errors and warnings | |
WordCount | 20% | An ideal page contains between 400 and 600 words.This page contains 2604 words | |
Server response time | 30% | A slow server slows down a website. This server responds 885.26% slower the average | |
Gzip compression | 30% | This site does not use Gzip compression. Pages may not display as fast as they could | |
Keywords in Domainname | 100% | There are important keywords in your domain name | |
Keywords in domain path | 100% | There are important keywords in the domain path | |
Structured Data | 100% | Structured data makes it easier for search engines to index your website | |
Inline css | 93% | Do not use inline css declarations. Inline css will slow down the rendering of the website. We detected 2 inline style declarations ( <a style="color:green">) with a size of 60 bytes | |
Excessive use of the same words | 100% | There is no indication that there are one or more keywords that are used excessively. | |
Frames or iframes | 20% | The use of (i)frames can lead to problems crawling your page. Wij found 2 frame(s) on your page | |
Flash | 100% | Perfect, we detected no flash objects on your page | |
Css | 100% | Perfect, we did not detect too many CSS files | |
Javascript | 30% | Wij detected too much (4) blocking JavaScript files. Try to combine or defer the loading of JavaScript files | |
Mobile Website | 100% | Perfect, we found a responsive design for mobile users | |
Most important heading | 100% | Perfect, we detected a correct use of the most important (h1) heading! | |
Normalized headings | 100% | Perfect, we found a correct use of normalized headings ! |
How would you like to have SEO advice for all your pages ?? Start your SEO Dashboard and optimize your website!
www.eisai.com images and descriptions
7 images found at www.eisai.com Images can improve the user experience for a website by making a pag visually appealing Images can also add extra keyword relevance to a webpage by using alt tags. Images can also slow down a website. If the width and height for a picture is not specified for a browser know in advance how large the image is. A browser must first load the picture and see before it knows how much space should be on the page. Upon reservation In the meantime, the browser can do little but wait. When the height and width for the plate are given in the HTML code, a browser just continues to build for a page while the images load in the background.
http://www.eisai.com/common/images/header/logo.svg height: height attribute not set width: width attribute not set description: /news/index.html |
|
http://www.eisai.com/common/images/icon_search.png height: height attribute not set width: width attribute not set description: no alt description found |
|
http://www.eisai.com/common/images/footer/to-top.png height: height attribute not set width: width attribute not set description: back to top |
|
http://www.eisai.com/common/images/logo_hhc.svg height: height attribute not set width: width attribute not set description: hhc human health care |
|
http://www.eisai.com/common/images/x-icon.svg height: height attribute not set width: width attribute not set description: x |
|
http://www.eisai.com/common/images/facebook-icon.svg height: height attribute not set width: width attribute not set description: facebook |
|
http://www.eisai.com/common/images/linkedin-icon.svg height: height attribute not set width: width attribute not set description: linkedin |
How are images contributing to your SEO site-wise ? Your leading content tool has the awnsers!